Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Z-DEVD-FMK

For research use only.

Catalog No.S7312 Synonyms: Caspase-3 Inhibitor

46 publications

Z-DEVD-FMK Chemical Structure

CAS No. 210344-95-9

Z-DEVD-FMK (Caspase-3 Inhibitor) is a specific, irreversible Caspase-3 inhibitor, and also shows potent inhibition on caspase-6, caspase-7, caspase-8, and caspase-10.

Size Price Stock Quantity  
USD 197 In stock
USD 590 In stock
USD 1270 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Z-DEVD-FMK has been cited by 46 publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-DEVD-FMK (Caspase-3 Inhibitor) is a specific, irreversible Caspase-3 inhibitor, and also shows potent inhibition on caspase-6, caspase-7, caspase-8, and caspase-10.
Targets
Caspase-3 [1]
In vitro

Z-DEVD-FMK (1–200 μM) inhibits D4-GDI cleavage and apoptosis in a concentration-dependent manner. [1] Z-DEVD-FMK reduces ceramide-induced cardiomyocyte death and significantly inhibits the activation of caspase 3. [3] Z-DEVD-FMK (100μM) attenuates OxyHb-induced cell detachment, reduced caspase-2 and -3 activities, abolishes OxyHb-induced DNA ladders, and prevents OxyHb-induced cleavage of PARP in cultured brain microvessel endothelial cells. [4] Z-DEVD-FMK (100 μM) blocks MPP+-induced increases in caspase-3 enzyme activity. Z-DEVD-FMK dose dependently blocks 6-OHDA-induced apoptotic cell death with IC50 of 18 μM. [5]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
duck embryo fibroblasts (DEFs) NWPPd3B4TnWwY4Tpc44h[XO|YYm= M3\LR|IhcMLi MVPl[oZm[3SrdnXsfUBxem:vb4Tl[EB3cXKjbDDy[ZBtcWOjdHnvci=> NISyWXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEixN|UxOCd-M{C4NVM2ODB:L3G+
OSCC cell NIjMfXFCeG:ydH;zbZMh[XO|YYm= M4XNVVIxKML3TR?= MlnTOFghcA>? NVTFUXNNemWmdXPlJJRp\SCjY4Tpeol1gSCxZjDjZZNx[XOnIEOgZY5lKGOjc4Dhd4UhQQ>? M3zFdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUezPVc5Lz5|MEW3N|k4QDxxYU6=
A549 MYTGeY5kfGmxbjDhd5NigQ>? NGjscGgzPSEQvF2= NEfk[XQzPCCq MX;zbYdvcW[rY3HueIx6KGmwaHnibZQhWk:VIHflcoVz[XSrb36gbY4hSTV2OTDj[Yxtew>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2MEewPUc,OzB{NEC3NFk9N2F-
HCT116 cells NUHBRnlXTnWwY4Tpc44h[XO|YYm= NEPHeWE2OOLCid88US=> MkG0NkBp M2CzVINwfHKnYYTt[Y51KHerdHigXJltd3CrbnWgeI8heHKndnXueIUhfGinIIj5cI9xcW6nLXnu[JVk\WRiaX7jdoVie2mwZzDhdI9xfG:|aYO= MmXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl|NkK2OlcoRjJ7M{[yOlY4RC:jPh?=
K562 cells NWm3O41ZTnWwY4Tpc44h[XO|YYm= M2\HeFIhcA>? MUHpcoNz\WG|ZXSgVk4hfmW{bnnjbYZtfWFiZYj0doFkfC2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdg>? NVfIc3BkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNlg{QDdpPkK5N|I5Ozh5PD;hQi=>
THP-1 cells MojHSpVv[3Srb36gZZN{[Xl? NHfDWnA2OCEQvF2= MWOyJIg> NIPPN3d{fWJvR{GgdIVicyCLbnjpZol1cW:wIHnuJGROWUFiaX7keYNm\CClZXzsJIRm[XSq MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ{NUGzOkc,Ojl{MkWxN|Y9N2F-

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
HAUSP / Kinesin 5B / GEP100 / SDCCAG3 / PARD3 / Lamin A/C / PARP ; 

PubMed: 24195789     


HeLa cells were treated with 1 μM STS for 24 hr in the presence or absence of the 100 μM caspase inhibitors (Z-VEID-FMK; caspase-6 inhibitor, Z-DEVD-FMK; caspase-3/-7 inhibitor, Z-VAD-FMK; pan-caspase inhibitor) pretreated to cells for 3 hr. After 24 hr, 䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뾠Ղ䐺痖暼瘿뾠Ղᾰƌ 뾠Ղà㺣痖뾠Ղ€𢡄뾤Ղ€䀷痗뾤Ղ౴뾤Ղ㵶痗뾤Ղ뺖᎒泌Itemｾ᎒

CLK3 / ADH4 / MDH1; 

PubMed: 24195789     


HeLa cells were treated with 1 μM STS for 24 hr in the presence or absence of the 100 μM caspase inhibitors (Z-VEID-FMK; caspase-6 inhibitor, Z-DEVD-FMK; caspase-3/-7 inhibitor, Z-VAD-FMK; pan-caspase inhibitor) pretreated to cells for 3 hr. After 24 hr, 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼

ORF57 / caspase 7 / caspase 3; 

PubMed: 20159985     


Inhibition of ORF57 cleavage by specific caspase inhibitors. BCBL-1 cells treated with VA in the presence of 50 μmpeptide-based caspase inhibitors, including pan-caspase inhibitor z-VAD-fmk, caspase-3/7 inhibitor z-DEVD-fmk , caspase-3/6 inhibitor z-VEID-䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

24195789 20159985
In vivo Z-DEVD-FMK, before and after injury, markedly reduces post-traumatic apoptosis, and significantly improved neurological recovery. [2]

Protocol

Kinase Assay:[5]
- Collapse

Caspase activity assay :

Caspase-3 and caspase-9 activities are measured using fluorescent-based substrate. After treatment, the cells are resuspended in lysis buffer (50 mM Tris HCl, 1 mM EDTA, and 10 mM EGTA) containing 10 mM digitonin for 20 min at 37°C. Supernatants are treated with either of the fluorogenic substrates Ac-DEVD-AFC for caspase-3 or Ac-LEHD-AFC for caspase-9 for 1 h at 37°C and fluorescence is measured at excitation at 400 nm and emission at 505 nm using a Gemini XS fluorescence plate reade
Cell Research:[5]
- Collapse
  • Cell lines: N27 cells
  • Concentrations: ~50 μM
  • Incubation Time: 24 hours
  • Method: N27 cells are incubated with 100 μM 6-OHDA for 24 h or 300 μM MPP+ for 36 h in the presence or absence of 50 μM Z-DEVD-FMK and cell death is determined by MTT (3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyl tetrazolium bromide) assay, which is widely used to assess cell viability. After treatment, the cells are incubated in serum-free medium containing 0.25 mg/ml MTT for 3 h at 37°C. Formation of formazan from tetrazolium is measured at 570 nm with a reference wavelength at 630 nm using a SpectraMax microplate reader.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Male Sprague Dawley rats with Brain trauma.
  • Dosages: 160 ng
  • Administration: Intracerebroventricular administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (149.55 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 400+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 668.66
Formula

C30H41FN4O12
CAS No. 210344-95-9
Storage powder
in solvent
Synonyms Caspase-3 Inhibitor
Smiles CC(C)C(C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)C(CCC(=O)OC)NC(=O)C(CC(=O)OC)NC(=O)OCC1=CC=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

Caspase Signaling Pathway Map

Related Caspase Products

  • MI-773 (SAR405838) New

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477 New

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Belnacasan (VX-765)

    Belnacasan (VX-765) is a potent and selective inhibitor of caspase-1 with Ki of 0.8 nM in a cell-free assay. Phase 2.

    Features:A potent and selective inhibitor of interleukin-converting enzyme/caspase-1.

  • PAC-1

    PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.

    Features:The first small molecule known to directly activate procaspase-3 to caspase-3.

  • Apoptosis Activator 2

    Apoptosis Activator 2 strongly induces caspase-3 activation, PARP cleavage, and DNA fragmentation which leads to the destruction of cells (Apaf-1 dependent) with IC50 of ~4 μM, inactive to HMEC, PREC, or MCF-10A cells.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • Tasisulam

    Tasisulam (LY573636) is an antitumor agent and an apoptosis inducer via the intrinsic pathway. Phase 3.

  • Navitoclax (ABT-263)

    Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Tags: buy Z-DEVD-FMK | Z-DEVD-FMK supplier | purchase Z-DEVD-FMK | Z-DEVD-FMK cost | Z-DEVD-FMK manufacturer | order Z-DEVD-FMK | Z-DEVD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID